Skip to content

The efficacy and safety evaluation of Xiao'er Biantong Granule in treating children’s functional constipation with dyspepsia syndrome: a multi-center, randomized, doubled-blind, placebo-controlled trial

The efficacy and safety evaluation of Xiao'er Biantong Granule in treating children's functional constipation with dyspepsia syndrome: a multi-center, randomized, doubled-blind, placebo-controlled trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003326
Enrollment
Unknown
Registered
2013-06-13
Start date
2013-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

children’s functional constipation with dyspepsia.

Interventions

A:Xiao‘er Biantong Granules, 1 to 3 years: take1/2 bag (5g), 3 times a day, 4 to 6 years: take 1 bag (5g), 2 times a day, =7years: take 1 bag (5g), 3 times a day

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with functional constipation; 2. Meeting the criteria of TCM syndrome of dyspepsia; 3. Aged 1 to 14 years; 4. Fully informed, voluntary consent, and signed the ICF by legal guardians.

Exclusion criteria

Exclusion criteria: 1. intestinal stenosis caused by Rectum, colon organic disease (such as cancer, inflammation, anal fissure, Crohn's disease, intestinal obstruction, adhesions, colon polyps, intestinal tuberculosis, etc.); 2. Caused by a Hirschsprungs discase, sigmoid long disease and neurological disorders, mental disorders, endocrine metabolic disorders; 3. Constipation caused by the systemic organic lesions; 4. outlet obstruction or mixed constipation; 5. Allergic children or allergic to the components of this preparation; 6. Combined with cardiovascular disease, cerebrovascular disease, hepatic disease, renal disease, hematopoietic system disorders or other severe diseases; 7. Positive fecal occult blood; 8. Have used other medication in treating this disease in the past 2 weeks.

Design outcomes

Primary

MeasureTime frame
Defecation interval time;Stool consistency score on Bristol stool scale;difficulty defecation;

Secondary

MeasureTime frame
Relief of constipation defined by modified ROME criteria;Sum score of TCM syndrome;recurrence rate during follow-up;

Countries

China

Contacts

Public ContactSiyuan Hu
husiyuan1963@sina.com+86 022 27432275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026